ESMO Asia 2023 | Strategies for patients with TNBC progressing on checkpoint inhibitors

While the vast majority of patients with triple negative breast cancer (TNBC) respond to checkpoint inhibitors such as pembrolizumab, Dr Michail Ignatiadis, MD, PhD from from Institut Jules Bordet and Université Libre de Bruxelle, Brussels, Belgium, discusses possible alternative strategies for those that do not. To prevent metastatic disease progression, he states it is necessary to assess PD-L1 expression in the patient to determine the extent of further checkpoint inhibitor administration. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.